Jul
AMA Releases Vaccine Code Changes
The update is for the CPT® 2025 production cycle, but three new codes are already in effect. The American Medical Association (AMA) updated its CPT® code set to reflect the vaccines currently available for the 2024-2025 influenza season. There are also two new vaccine codes for pneumonia and meningitis. The new codes and one code revision will be published in the CPT® 2025 publication, but some of the changes are already in effect. Flu Vaccine Code Changes According to the Centers for Disease Control and Prevention, the updated 2024-2025 flu vaccines will all be trivalent and will protect against an H1N1, H3N2 and a B/Victoria lineage virus. The Medicare flu season payment allowances and effective dates for the 2024-2025 season aren’t published yet, but two new flu vaccine codes effective July 1, 2024, are: 90637 Influenza virus vaccine, quadrivalent (qIRV), mRNA; 30 mcg/0.5 mL dosage, for intramuscular use 90638 … 60 mcg/0.5 mL dosage, for intramuscular use These vaccines are FDA approval pending. There is also one revised code: 90661 Influenza virus vaccine, trivalent (ccIIV3), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use This code descriptor change is effective Jan. 1, 2025. Other Vaccine Code Changes Also accepted for the 2025 CPT® production cycle is this new vaccine code: 90684 Pneumococcal conjugate vaccine, 21 valent (PCV21), for intramuscular use This vaccine is FDA approved as of June 20, 2024, and the code is effective as of June 17, 2024. Another new immunization administration code, accepted for the CPT® 2025 production cycle, is: 90624 Meningococcal pentavalent vaccine, Men B-4C recombinant proteins and outer membrane vesicle and conjugated Men A, C, W, Y-diphtheria toxoid carrier, for intramuscular use The code is effective Oct. 1, 2024, and the vaccine is FDA approval pending. RSV Vaccine Receives FDA Approval Moderna’s respiratory syncytial virus (RSV) vaccine received FDA approval on May 31. CPT® code 90683 Respiratory syncytial virus vaccine, mRNA lipid nanoparticles, for intramuscular use will be published in CPT® 2025. RSV-positive tests and hospitalizations remain low in the United States, along with national vaccination coverage, according to the Centers for Disease Control and Prevention. See the AMA document for the official notice of these CPT® 2025 early releases. Reference: Dustman, R. (2024, July 2). AMA releases vaccine code changes – AAPC Knowledge Center. AAPC Knowledge Center. https://www.aapc.com/blog/90916-ama-releases-immunization-vaccine-code-changes/
